Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

The United States is seeing a second peak in flu cases this season. After doctor’s office visits for flu dipped early this ...

Robert F. Kennedy Jr.'s nomination for Health and Human Services (HHS) secretary cleared a key Senate committee today. Should ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s ...

US stock futures down on Tues, focus on PepsiCo, NXP Semiconductors, Pfizer earnings. UBS reports strong Q4, EA to release ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Related to Kennedy’s known hostility to pharmaceutical manufacturers is his criticism of vaccines — which was the primary focus of Democrats’ attacks on him. Their questions not only distorted his ...